The addition of the residual with the second intrinsic mode function (IMF) based on ensemble empirical mode decomposition (EEMD) analysis to place the EEMD results in context with... by Jose Dominick Guballa (19739909)

Subjects:

Scanning electron microscope (SEM) images of common coccolithophore species identified in the study interval in core SO130-289KL. by Jose Dominick Guballa (19739909)

Subjects:

Wavelet analysis of the major coccolithophore species in core SO130-289KL. by Jose Dominick Guballa (19739909)

Subjects:

Comparison of the coccolithophore assemblage to paleo-proxy records between 74.40 to 73.40 ka. by Jose Dominick Guballa (19739909)

Subjects:

Coccolithophore relative abundance data from core SO130-289KL from 1854.6 cm to 1820.4 cm. by Jose Dominick Guballa (19739909)

Subjects:

General seasonal hydrography of the northern Arabian Sea. by Jose Dominick Guballa (19739909)

Subjects:

Median ± IQR <i>M. plutonius</i> bacterial load (CFU/bee) of newly emerged summer worker bees inoculated with 1 × 10⁷ CFU/bee <i>M. plutonius</i> 2019BC1 and/or treated... by Midhun Sebastian Jose (19336846)

Experimental design used in broiler chickens. by Oumayma Arbani (21001472)

Subjects:

CTL response following combination therapy with NDV. by Hedieh Zargaran (21410233)

Table 1_Dual variants of uncertain significance in a case of hyper-IgM syndrome: implications for diagnosis and management.docx by Nourhen Agrebi (14151222)

“…</p>Objective<p>This study aims to elucidate the clinical implications of concurrent AICDA and IKBKB homozygous variants in a pediatric patient diagnosed with hyper-IgM syndrome.</p>Methods<p>We present immunological and genetic analysis of a Tunisian patient with two homozygous variants of uncertain significance (VUSs) in the IKBKB and AICDA genes, suspected of causing hyper-IgM and immune deficiency. …”

Sequence of <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

Subjects:

Predicted <i>cis</i>-acting elements in <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

Subjects:

Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

S1 Graphical - by Agnieszka Murawska (11021928)

Subjects:

Col outcomes QR. by Felipe Agudelo-Hernández (20790521)

“…</p><p>Results</p><p>Statistically significant improvements were observed in human rights understanding, reduced stigmatizing attitudes toward mental health and decreased authoritarianism. …”

Pre-post comparison of study variables. by Felipe Agudelo-Hernández (20790521)

“…</p><p>Results</p><p>Statistically significant improvements were observed in human rights understanding, reduced stigmatizing attitudes toward mental health and decreased authoritarianism. …”

DataSheet1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”

DataSheet3_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”

DataSheet2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”